BioMarin Opens Office in Brisbane to Support Expanding Operations
"With the rapid growth of our sales and product pipeline over the pastfour years, BioMarin has become one of the largest employers in the NorthBay," said Mark Wood, BioMarin's Vice President of Human Resources. "The newoffice in Brisbane will help us sustain this growth and provide access totalent in the vibrant peninsula bio-pharma marketplace."
"BioMarin is making tremendous progress both domestically andinternationally. With three drugs on the market and a rapidly growing productpipeline, we have accomplished a great deal in our short corporate history.We are very excited to further our expansion by opening new offices on thepeninsula and adding much needed capacity to local operations in Novato,"added Jean-Jacques Bienaime, BioMarin's Chief Executive Officer.
BioMarin opened its new Brisbane office on October 1, 2008 and hasinitiated targeted recruiting efforts for Brisbane-based positions. Thecompany employs approximately 600 employees worldwide and has been recognizedas one of the Bay Area's Best Places to Work for two years running.
For more information, please visit the BioMarin website athttp://www.BMRN.com.
BioMarin develops and commercializes innovative biopharmaceuticals forserious diseases and medical conditions. The company's product portfoliocomprises three approved products and multiple clinical and preclinicalproduct candidates. Approved products include Naglazyme(R) (galsulfase) formucopolysaccharidosis VI (MPS VI), a product wholly developed andcommercialized by BioMarin; Aldurazyme(R) (laronidase) formucopolysaccharidosis I (MPS I), a product which BioMarin developed through a50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterindihydrochloride) Tablets, a product for the treatment of phenylketonuria(PKU), developed in partnership with Merck Serono, a division of Merck KGaA ofDarmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascularindications, which is currently in Phase 2 clinical development for thetreatment of peripheral arterial disease and sickle cell disease, and PEG-PAL(PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU.
For additional information, please visit www.BMRN.com. Information onBioMarin's website is not incorporated by reference into this press release.
BioMarin(R), Naglazyme(R) and Kuvan(R) are a registered trademarks ofBioMarin Pharmaceutical Inc.Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC. Contacts: Investors Media Eugenia Shen Susan Berg BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 506-6570 (415) 506-6594
SOURCE BioMarin Pharmaceutical Inc.
You May Also Like